Floatz logo

Ivonescimab

Efficacy

Hunan Province Tumor Hospitalmonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Efficacy cohort.

View all 37

Same molecule, other indications

Ivonescimab is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
64 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →